An Epstein-Barr virus-associated superantigen

doi:10.1084/jem.184.3.971

This Article

	Full Text (PDF, 1249K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Sutkowski, N.
	Articles by Huber, B. T.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Sutkowski, N.
	Articles by Huber, B. T.


Social Bookmarking

	What's this?

ARTICLES

An Epstein-Barr virus-associated superantigen

N Sutkowski, T Palkama, C Ciurli, RP Sekaly, DA Thorley-Lawson and BT Huber
Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.

More than 90% of adults are latently infected with Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, a self-limiting lymphoproliferative disease characterized by extensive T cell activation. Reactivation of this herpesvirus during immunosuppression is often associated with oncogenesis. These considerations led us to analyze the early events that occur after exposure of the immune system to EBV. Strong major histocompatibility complex (MHC) class II- dependent but not MHC-restricted, T cell proliferation was observed in vitro in response to autologous, lytically infected EBV-transformed B cells. By measuring the appearance of the early activation marker CD69 on individual T cell V beta subsets, we could demonstrate selective activation of human V beta 13- T cells. This was confirmed with murine T cell hybridomas expressing various human BV genes. While EBV- Burkitt's lymphoma cells were nonstimulatory, they induced V beta- restricted T cell activation after EBV infection. EBV specific activation was also demonstrated in cord blood cells, excluding a recall-antigen response. Thus, all of the characteristics of a superantigen-stimulated response are seen, indicating that induction of the EBV lytic cycle is associated with the expression of a superantigen in B cells. A model is presented proposing a role for the superantigen in infection, latency, and oncogenesis.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Tai, A., O'Reilly, E., Alroy, K., Simon, K., Munger, K., Huber, B., Ascherio, A (2008). Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. Mult Scler 14: 1175-1180 [Abstract]
Evans, A. G., Moser, J. M., Krug, L. T., Pozharskaya, V., Mora, A. L., Speck, S. H. (2008). A gammaherpesvirus-secreted activator of V{beta}4+ CD8+ T cells regulates chronic infection and immunopathology. JEM 205: 669-684 [Abstract] [Full Text]
Voisset, C., Weiss, R. A., Griffiths, D. J. (2008). Human RNA "Rumor" Viruses: the Search for Novel Human Retroviruses in Chronic Disease. Microbiol. Mol. Biol. Rev. 72: 157-196 [Abstract] [Full Text]
Tai, A. K., Lin, M., Chang, F., Chen, G., Hsiao, F., Sutkowski, N., Huber, B. T. (2006). Murine Vbeta3+ and Vbeta7+ T Cell Subsets Are Specific Targets for the HERV-K18 Env Superantigen.. J. Immunol. 177: 3178-3184 [Abstract] [Full Text]
Hsiao, F. C., Lin, M., Tai, A., Chen, G., Huber, B. T. (2006). Cutting Edge: Epstein-Barr Virus Transactivates the HERV-K18 Superantigen by Docking to the Human Complement Receptor 2 (CD21) on Primary B Cells. J. Immunol. 177: 2056-2060 [Abstract] [Full Text]
Williams, H., Crawford, D. H. (2006). Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 107: 862-869 [Abstract] [Full Text]
Sutkowski, N., Chen, G., Calderon, G., Huber, B. T. (2004). Epstein-Barr Virus Latent Membrane Protein LMP-2A Is Sufficient for Transactivation of the Human Endogenous Retrovirus HERV-K18 Superantigen. J. Virol. 78: 7852-7860 [Abstract] [Full Text]
Bickham, K., Goodman, K., Paludan, C., Nikiforow, S., Tsang, M. L., Steinman, R. M., Munz, C. (2003). Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro. JEM 198: 1653-1663 [Abstract] [Full Text]
Asada, H., Miyagawa, S., Sumikawa, Y., Yamaguchi, Y., Itami, S., Suguri, S., Harada, M., Tokura, Y., Ishihara, S., Ohshima, S., Yoshikawa, K. (2003). CD4+ T-Lymphocyte-Induced Epstein-Barr Virus Reactivation in a Patient With Severe Hypersensitivity to Mosquito Bites and Epstein-Barr Virus-Infected NK Cell Lymphocytosis. Arch Dermatol 139: 1601-1607 [Abstract] [Full Text]
Varela-Calvino, R., Sgarbi, G., Wedderburn, L. R., Dayan, C. M., Tremble, J., Peakman, M. (2001). T Cell Activation by Coxsackievirus B4 Antigens in Type 1 Diabetes Mellitus: Evidence for Selective TCR V{beta} Usage Without Superantigenic Activity. J. Immunol. 167: 3513-3520 [Abstract] [Full Text]
Nakamura, H., Zarycki, J., Sullivan, J. L., Jung, J. U. (2001). Abnormal T Cell Receptor Signal Transduction of CD4 Th Cells in X-Linked Lymphoproliferative Syndrome. J. Immunol. 167: 2657-2665 [Abstract] [Full Text]
Torres, B. A., Kominsky, S., Perrin, G. Q., Hobeika, A. C., Johnson, H. M. (2001). Superantigens: The Good, the Bad, and the Ugly. Exp. Biol. Med. 226: 164-176 [Abstract] [Full Text]
Hardy, C. L., Silins, S. L., Woodland, David. L., Blackman, M. A. (2000). Murine {gamma}-herpesvirus infection causes V{beta}4-specific CDR3-restricted clonal expansions within CD8+ peripheral blood T lymphocytes. Int Immunol 12: 1193-1204 [Abstract] [Full Text]
Spieker, T., Herbst, H. (2000). Distribution and Phenotype of Epstein-Barr Virus-Infected Cells in Inflammatory Bowel Disease. Am. J. Pathol. 157: 51-57 [Abstract] [Full Text]
Kukreja, (1999). Autoimmunity and Diabetes. J. Clin. Endocrinol. Metab. 84: 4371-4378 [Abstract] [Full Text]
Hoshino, Y., Morishima, T., Kimura, H., Nishikawa, K., Tsurumi, T., Kuzushima, K. (1999). Antigen-Driven Expansion and Contraction of CD8+-Activated T Cells in Primary EBV Infection. J. Immunol. 163: 5735-5740 [Abstract] [Full Text]
Fraser, P A, Lu, L-Y, DeCeulaer, K, Schur, P H, Fici, D, Awdeh, Z, Ding, W-Z, Levitan, E, Lew, R, Uko, G, Gonzalez, C (1999). CD4 TCRBV CDR3 Analysis in prevalent SLE Cases from two ethnic Groups. Lupus 8: 311-319 [Abstract]
Tan, L. C., Gudgeon, N., Annels, N. E., Hansasuta, P., O'Callaghan, C. A., Rowland-Jones, S., McMichael, A. J., Rickinson, A. B., Callan, M. F. C. (1999). A Re-Evaluation of the Frequency of CD8+ T Cells Specific for EBV in Healthy Virus Carriers. J. Immunol. 162: 1827-1835 [Abstract] [Full Text]
Luppi, P., Rudert, W. A., Zanone, M. M., Stassi, G., Trucco, G., Finegold, D., Boyle, G. J., Nido, P. D., McGowan, F. X. Jr, Trucco, M. (1998). Idiopathic Dilated Cardiomyopathy : A Superantigen-Driven Autoimmune Disease. Circulation 98: 777-785 [Abstract] [Full Text]
Duboise, M., Guo, J., Czajak, S., Lee, H., Veazey, R., Desrosiers, R. C., Jung, J. U. (1998). A Role for Herpesvirus Saimiri orf14 in Transformation and Persistent Infection. J. Virol. 72: 6770-6776 [Abstract] [Full Text]
Schirrmacher, V., Beutner, U., Bucur, M., Umansky, V., Rocha, M., von Hoegen, P. (1998). Loss of Endogenous Mouse Mammary Tumor Virus Superantigen Increases Tumor Resistance. J. Immunol. 161: 563-570 [Abstract] [Full Text]
Grigg, M. E., McMahon, C. W., Morkowski, S., Rudensky, A. Y., Pullen, A. M. (1998). Mtv-1 Superantigen Trafficks Independently of Major Histocompatibility Complex Class II Directly to the B-Cell Surface by the Exocytic Pathway. J. Virol. 72: 2577-2588 [Abstract] [Full Text]
Steven, N.M., Annels, N.E., Kumar, A., Leese, A.M., Kurilla, M.G., Rickinson, A.B. (1997). Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus-induced Cytotoxic T Cell Response. JEM 185: 1605-1618 [Abstract] [Full Text]
Tripp, R. A., Hamilton-Easton, A. M., Cardin, R. D., Nguyen, P., Behm, F. G., Woodland, D. L., Doherty, P. C., Blackman, M. A. (1997). Pathogenesis of an Infectious Mononucleosis-like Disease Induced by a Murine {gamma}-Herpesvirus: Role for a Viral Superantigen?. JEM 185: 1641-1650 [Abstract] [Full Text]